Literature DB >> 31597665

Risk of Anal Cancer Following Benign Anal Disease and Anal Cancer Precursor Lesions: A Danish Nationwide Cohort Study.

Mette T Faber1, Kirsten Frederiksen2, Joel M Palefsky3, Susanne K Kjaer4,5.   

Abstract

BACKGROUND: Human papillomavirus (HPV) is associated with the majority of anal high-grade intraepithelial neoplasia (AIN) and anal cancers. Little is known about the risk of anal cancer following a diagnosis of benign anal disease and AIN.
METHODS: Using data from nationwide, population-based Danish registries, a cohort of 126,174 individuals with either non-neoplastic anal disease or AIN 1 to 3 during 1970 to 2016 was followed until first occasion of anal cancer. Information on HIV status was obtained from the Danish HIV Cohort Study. The absolute risk of anal cancer was estimated using the Aalen-Johansen estimator taking into account censoring at emigration and end of follow-up and competing risk at time of death. Standardized incidence ratios (SIR) for anal cancer among individuals with non-neoplastic anal disease, including inflammatory lesions, hemorrhoids, and polyps, were estimated in Poisson models. Sex-, age-, and calendar period-specific national population rates were estimated using the Danish National Pathology Registry.
RESULTS: Anal cancer risk increased with increasing severity of lesions, reaching 4% 5 years after diagnosis of AIN3. Even among those with non-neoplastic anal lesions, particularly inflammatory lesions, anal cancer risk was significantly higher than expected from Danish national anal cancer rates (SIR = 2.8; 95% confidence intervals, 2.3-3.2). The absolute 5-year risk of anal cancer following AIN3 was considerably higher among HIV-positive (14.1%) than HIV-negative (3.2%) individuals.
CONCLUSIONS: Anal cancer risk increases with increasing severity of lesions and is especially high among HIV-positive individuals. IMPACT: Vaccination against HPV is important in the prevention of both high-grade AIN and anal cancer. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31597665     DOI: 10.1158/1055-9965.EPI-19-0601

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  6 in total

1.  Design of the ANal Cancer/HSIL Outcomes Research study (ANCHOR study): A randomized study to prevent anal cancer among persons living with HIV.

Authors:  Jeannette Y Lee; Shelly Y Lensing; J Michael Berry-Lawhorn; Naomi Jay; Teresa M Darragh; Stephen E Goldstone; Timothy J Wilkin; Elizabeth A Stier; Mark Einstein; Julia C Pugliese; Joel M Palefsky
Journal:  Contemp Clin Trials       Date:  2022-01-10       Impact factor: 2.226

Review 2.  [Anal dysplasia and anal cancer].

Authors:  Ulrike Wieland; Frank Oellig; Alexander Kreuter
Journal:  Hautarzt       Date:  2020-04       Impact factor: 0.751

Review 3.  Anal dysplasia and anal cancer. English version.

Authors:  Ulrike Wieland; Frank Oellig; Alexander Kreuter
Journal:  Hautarzt       Date:  2020-12       Impact factor: 0.751

Review 4.  Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers.

Authors:  Vetri Sudar Jayaprakasam; Viktoriya Paroder; Heiko Schöder
Journal:  Semin Nucl Med       Date:  2021-05-06       Impact factor: 4.802

5.  Risk of Anorectal Cancer Associated with Benign Anal Inflammatory Diseases: A Retrospective Matched Cohort Study.

Authors:  Wonjeong Chae; Seung Yeon Kang; Sung-In Jang; Yoon Dae Han
Journal:  Int J Environ Res Public Health       Date:  2022-06-17       Impact factor: 4.614

6.  A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer.

Authors:  Mette T Faber; Kirsten Frederiksen; Joel M Palefsky; Susanne K Kjaer
Journal:  Int J Cancer       Date:  2022-06-15       Impact factor: 7.316

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.